Abstract
Typical cases of primary neurodegenerative diseases causing dementia, such as Alzheimer’s disease (AD), diffuse Lewy body disease, frontotemporal lobar degeneration (FTLD), and corticobasal degeneration, show characteristic clinical signs and symptoms, but there are some cases in which the differential diagnosis among neurodegenerative dementias is difficult because of their atypical clinical presentation. Considering recent findings in molecular genetics of familial cases of AD and FTLD, the relationship between causative genes and clinical signs is becoming more complicated, and the concept of an AD-FTLD spectrum is proposed. Protein fragments derived from amyloid precursor proteins, tau and TDP-43, are deposited in the cerebral tissue of patients with AD and FLTD in different degrees. In familial cases, these deposited protein fragments are caused by mutations in the precursor protein genes. The majority of cases of AD and FTLD are sporadic, wherein loss of function of presenilin and progranulin increases the risk of these neurodegenerative disorders. Under the concept of AD-FTLD, it is more helpful to elucidate the common neurodegenerative pathway in which aggregated protein fragments are deposited after partial proteolysis, phosphorylation, and ubiquitination, leading to the formation of amyloid angiopathy, senile plaque, neurofibrillary tangles, and the inclusion body of FTLD.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Ferri CP, Prince M, Brayne C et al (2005) Global prevalence of dementia: a Delphi consensus study. Lancet 366:2112–2117
Breteler MM, Claus JJ, van Duijn CM et al (1992) Epidemiology of Alzheimer’s disease. Epidemiol Rev 14:59–82
Graff-Radford NR, Woodruff BK (2007) Frontotemporal dementia. Semin Neurol 27:48–57
Neary D, Snowden JS, Gustafson L et al (1998) Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology 51(6):1546–1554
Goate A, Chartier-Harlin MC, Mullan M et al (1991) Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer’s disease. Nature (Lond) 349:704–706
Sherrington R, Rogaev EI, Liang Y et al (1995) Cloning of a gene bearing missense mutations in early-onset familial Alzheimer’s disease. Nature (Lond) 375:754–760
Levy-Lahad E, Wasco W, Poorkaj P et al (1995) Candidate gene for the chromosome 1 familial Alzheimer’s disease locus. Science 269:973–977
Hardy J (1997) Amyloid, the presenilins and Alzheimer’s disease. Trends Neurosci 20:154–159
De Strooper B (2003) Aph-1, Pen-2, and nicastrin with presenilin generate an active gamma-secretase complex. Neuron 38:9–12
Bird TD (2008) Genetic aspects of Alzheimer disease. Genet Med 10:231–239
Strittmatter WJ, Saunders AM, Schmechel D et al (1993) Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci USA 90:1977–1981
Farrer LA, Cupples LA, Haines JL et al (1997) Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOε and Alzheimer disease meta analysis consortium. JAMA 278:1349–1356
Corder EH, Saunders AM, Strittmatter WJ et al (1993) Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science 261:921–923
Mahley RW, Weisgraber KH, Huang Y (2006) Apolipoprotein E4: a causative factor and therapeutic target in neuropathology, including Alzheimer’s disease. Proc Natl Acad Sci USA 103:5644–5651
Drzezga A, Grimmer T, Henriksen G et al (2009) Effect of APOε genotype on amyloid plaque load and gray matter volume in Alzheimer disease. Neurology 72:1487–1494
Reiman EM, Chen K, Liu X et al (2009) Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer’s disease. Proc Natl Acad Sci USA 106:6820–6825
Rademakers R, Hutton M (2007) The genetics of frontotemporal lobar degeneration. Curr Neurol Neurosci Rep 7:434–442
Hutton M, Lendon CL, Rizzu P et al (1998) Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17. Nature (Lond) 393:702–705
Watts GD, Wymer J, Kovach MJ et al (2004) Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosin-containing protein. Nat Genet 36:377–381
Skibinski G, Parkinson NJ, Brown JM et al (2005) Mutations in the endosomal ESCRTIII complex subunit CHMP2B in frontotemporal dementia. Nat Genet 37:806–808
Baker M, MacKenzie IR, Pickering-Brown SM et al (2006) Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature (Lond) 442:916–919
Cruts M, Gijselinck I, van der Zee J et al (2006) Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21. Nature (Lond) 442:920–924
He Z, Bateman A (2003) Progranulin (granulin–epithelin precursor, PC-cell-derived growth factor, acrogranin) mediates tissue repair and tumorigenesis. J Mol Med 81:600–612
He Z, Ong CH, Halper J et al (2003) Progranulin is a mediator of the wound response. Nat Med 9:225–229
Van Damme P, Van Hoecke A, Lambrechts D et al (2008) Progranulin functions as a neurotrophic factor to regulate neurite outgrowth and enhance neuronal survival. J Cell Biol 181:37–41
Neumann M, Sampathu DM, Kwong LK et al (2006) Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 314:130–133
Buratti E, Baralle FE (2008) Multiple roles of TDP-43 in gene expression, splicing regulation, and human disease. Front Biosci 13:867–878
Gregory RI, Yan KP, Amuthan G et al (2004) The microprocessor complex mediates the genesis of microRNAs. Nature (Lond) 432:235–240
Amador-Ortiz C, Lin WL, Ahmed Z et al (2007) TDP-43 immunoreactivity in hippocampal sclerosis and Alzheimer’s disease. Ann Neurol 61:435–445
Higashi S, Iseki E, Yamamoto R et al (2007) Concurrence of TDP-43, tau and alpha-synuclein pathology in brains of Alzheimer’s disease and dementia with Lewy bodies. Brain Res 1184:284–294
Nakashima-Yasuda H, Uryu K, Robinson J et al (2007) Co-morbidity of TDP-43 proteinopathy in Lewy body related diseases. Acta Neuropathol 114:221–229
Kabashi E, Valdmanis PN, Dion P et al (2008) TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis. Nat Genet 40:572–574
Sreedharan J, Blair IP, Tripathi VB et al (2008) TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science 319:1668–1672
Morita M, Al-Chalabi A, Andersen PM et al (2006) A locus on chromosome 9p confers susceptibility to ALS and frontotemporal dementia. Neurology 66:839–844
Vance C, Al-Chalabi A, Ruddy D et al (2006) Familial amyotrophic lateral sclerosis with frontotemporal dementia is linked to a locus on chromosome 9p13.2–21.3. Brain 129:868–876
Rovelet-Lecrux A, Hannequin D, Raux G et al (2006) APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy. Nat Genet 38:24–26
Sleegers K, Brouwers N, Gijselinck I et al (2006) APP duplication is sufficient to cause early onset Alzheimer’s dementia with cerebral amyloid angiopathy. Brain 129:2977–2983
Wisniewski KE, Dalton AJ, McLachlan C et al (1985) Alzheimer’s disease in Down’s syndrome: clinicopathologic studies. Neurology 35:957–961
Singleton AB, Farrer M, Johnson J et al (2003) Alpha-synuclein locus triplication causes Parkinson’s disease. Science 302:841
Chartier-Harlin MC, Kachrgus J, Roumier C et al (2004) Alpha-synuclein locus duplication as a cause of familial Parkinson’s disease. Lancet 364:1167–1169
Brouwers N, Sleegers K, Engelborghs S et al (2006) Genetic risk and transcriptional variability of amyloid precursor protein in Alzheimer’s disease. Brain 129:2984–2991
Theuns J, Brouwers N, Engelborghs S et al (2006) Promoter mutations that increase amyloid precursor-protein expression are associated with Alzheimer disease. Am J Hum Genet 78:936–946
Crook R, Verkkoniemi A, Perez-Tur J et al (1998) A variant of Alzheimer’s disease with spastic paraparesis and unusual plaques due to deletion of exon 9 of presenilin 1. Nat Med 4:452–455
Rovelet-Lecrux A, Deramecourt V, Legallic S et al (2008) Deletion of the progranulin gene in patients with frontotemporal lobar degeneration or Parkinson disease. Neurobiol Dis 31:41–45
Rovelet-Lecrux A (2009) Partial deletion of the MAPT gene: a novel mechanism of FTDP-17. Hum Mutat 30:E591–E602
Wang WX, Rajeev BW, Stromberg AJ et al (2008) The expression of microRNA miR-107 decreases early in Alzheimer’s disease and may accelerate disease progression through regulation of beta-site amyloid precursor protein-cleaving enzyme 1. J Neurosci 28:1213–1223
Lukiw WJ, Zhao Y, Cui JG (2008) An NF-kB-sensitive micro RNA-146amediated inflammatory circuit in Alzheimer disease and in stressed human brain cells. J Biol Chem 283:31315–31322
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2010 Springer
About this chapter
Cite this chapter
Takeda, M. et al. (2010). AD-FTLD Spectrum: New Understanding of the Neurodegenerative Process from the Study of Risk Genes. In: Miyoshi, K., Morimura, Y., Maeda, K. (eds) Neuropsychiatric Disorders. Springer, Tokyo. https://doi.org/10.1007/978-4-431-53871-4_17
Download citation
DOI: https://doi.org/10.1007/978-4-431-53871-4_17
Publisher Name: Springer, Tokyo
Print ISBN: 978-4-431-53870-7
Online ISBN: 978-4-431-53871-4
eBook Packages: MedicineMedicine (R0)